Oral mucositis (OM) is a common side effect experienced during haematopoietic SCT (HSCT), and it can have a significant impact on the quality of life of patients. A descriptive nurse-led study was undertaken in 19-member centres of the Italian national transplant group (GITMO) evaluating incidence, severity and duration of OM in patients undergoing HSCT. Data from 1841 patients between 2002 and 2006 was analyzed. Initial medical history and oral cavity assessment was performed. Assessment was repeated on the day of transplant, then daily, using the WHO (World Health Organisation) oral toxicity scale. A total of 71% of the patients evaluated developed mucositis and 21.6% developed severe mucositis. Duration of OM in most cases lasted for 10-14 days and resolved along with marrow reconstitution. Oral mucostitis is a frequent side effect in patients undergoing HSCT. The onset of severe mucositis seems to be related to the conditioning regimen used. This database provides a descriptive overview of the incidence and severity of mucositis and has encouraged participating centres to
Introduction
Oral mucositis (OM) induced by anti-neoplastic treatment is a very common side effect occuring in 75-99% patients. [1] [2] [3] [4] It is burdensome and can interfere with treatment administration at full dose. The ulcerative lesions produced by this stomatic toxicity are painful and potential sites for secondary infection or ports of entry for endogenous flora. Furthermore, the pain and suffering in patients affected is important and can worsen their quality of life. [5] [6] [7] According to Sonis, 1, 6, 7 mucositis is a complex biological process that develops in five interdependent phases (initiation, the primary damage response-messaging and signalling, amplification, ulceration and healing) that are the consequence of a series of factors, including cytokinemediated actions, the effects of chemotherapy on the epithelium, the generation of reactive oxigen species and the bacterial flora of the oral cavity. Severity of OM is also conditioned by the neutrophil level and the patient's age.
The most common sites are the isthmus of the mouth, mucosa of the lips and cheeks, floor of the mouth, the ventral surface of the tongue and it can also involve the initial part of the oesophageal mucosa. 7, 8 OM generally manifests with signs of erythema and ulceration along with pain and intolerance of hot, cold, acid and spicy foods. Such complications can compromise verbal communication, interfere with oral drug assumption and require a particular diet. 9, 10 About 40% of patients treated with chemotherapy at standard doses develop mucositis and of these, around 50% develop lesions that require modifications or a suspension of the treatment programme. 6 In patients undergoing haematopoietic SCT (HSCT), both autologous and allogeneic, mucositis has a highly variable incidence ranging from 75 to 99% of cases, 1, 4 whereas all patients treated with local radiotherapy develop mucositis, due to the effects on the head and neck regions. 1, 9 The patients' oral hygiene can also modify the incidence and severity of OM. 4, 9 Patients with good oral hygiene and dental health, tend to have fewer episodes of mucositis. There seems to be a genetic influence on the inflammatory response, which may partially explain the different response of patients to therapy and to the development of OM.
Oral care protocols are based on two levels of intervention: non-medicated vs medicated strategies. The nonmedicated oral care protocol focuses on topical therapy and emphasizes frequent rinsing with 0.9% saline or sodium bicarbonate solutions. Additional interventions may include tooth brushing with toothpaste, dental flossing, sucking on ice chips and rinsing with chlorhexidine digluconate or hydrogen peroxide. 11, 12 Because of limited data defining the efficacy of these various practises for improved oral health during HSCT, oral care interventions across the institutions involved in this study have tended to vary significantly.
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The intensity and modality of staff monitoring compliance with these practices also vary. In some centres, the primary responsibility for monitoring rests with the nurses, whereas in other centres responsibility lies with a comprehensive, research-based team, which includes physicians, dentists, dental hygienists and nurses.
The medicated oral care protocols include the parenteral administration of antibiotics and pain-relief systemic drugs.
OM is an important risk factor for systemic infections and neutropenic patients with mucositis have a four-fold higher risk of sepsis compared with patients without mucositis. Thus, mucositis can be described as an onerous complication for prolonging hospitalization in patients undergoing autologous HSCT, 13 with an increase in health costs of USD 4500 per day and a total cost increase of USD 17 000-22 500 per patient. 6, 7 In view of the high incidence of OM in patients undergoing HSCT, [1] [2] [3] [4] the Nurses Advisory Committee of the National Transplant Group (Gruppo Italiano Trapianto di Midollo Osseo-GITMO) proposed the founding of a multicentre database on the incidence and severity of OM in patients undergoing HSCT. The presentation of the proposal and database was proposed at GITMO's national annual meeting in May 2002. Further details are available in the proposal. 14 
Objectives
The research had the following objectives:
To evaluate the incidence and severity of OM in patients undergoing HSCT, in national (GITMO) centres, participating in this study.
To activate a network of data exchange and collection regarding nursing care issues among the nurses of the national GITMO centres.
Patients and methods
Data were collected on patients affected by haematooncological diseases undergoing HSCT at BM Transplant Units, which are GITMO members.
Patients who were 'in-patients' for less than 10 days from HSCT were excluded, as were patients with mucositis at the moment of admission for transplant.
The WHO scale was used to assess the oral cavity and identify mucositis and to determine acute and sub-acute toxicity of chemotherapy and anti-tumor therapy in general. 1 The WHO scale consists of five grades, which describe the gradual and progressive evolution of OM. An oral cavity with no lesions corresponds to Grade 0, whereas Grade 4, considered as a severe mucositis, has the presence of marked tissue changes with erythema and ulceration involving almost all of the mucosa and/or bleeding, marked pain and inability to eat.
The scale is easy to use, well recognised, valid and reproducible and also sufficiently sensitive for use in different clinical situations (that is, mucositis caused by chemotherapy and/or radiotherapy). The scale can provide an accurate description of the anatomical changes of the mucosa. 1, 2, 8 The data were analyzed in relation to all patients, including those who were not followed until resolution of OM.
The transplant centres included in the study were those that agreed to the proposal and which were able to guarantee accurate data collection. For each centre, a contact nurse was identified to coordinate their centre's collaboration with the proposal, and this person was responsible for compiling the database.
The oral cavity of patients in the transplant unit was evaluated (to include: absence of pathologies, such as abscesses, granulomas, caries, gingivitis, and so on, the absence of traumatic factors, for example, broken or chipped dentures, which may compromise the integrity of the mucosa and oral hygiene). The assessment was performed by a doctor in the preparatory phase of HSCT and in which problems were identified, the patient was referred for a specialist opinion. Therapeutic interventions and any necessary dental work was undertaken before admission to the transplant unit.
Nurses collected patient data on such dental interventions (dental overview, specialist opinions, treatment of caries and eventual removal and tartar removal), and daily evaluation of the condition of the oral cavity from the day of the transplant to the resolution of mucositis (absence of mucositis for at least three consecutive days shown by Grade 0) 14 or until the patients were discharged from the transplant unit. Each participating centre used different tools for the registration of relevant data; some centres registered data in the patients' nursing notes, whereas other centres registered data in the patients' general notes.
The data were collected in the database using Microsoft Excel. The data were elaborated using the Microsoft Access programme. The data were stratified according to age. A statistical comparison was then made using w 2 -test. The representatives of centres wishing to participate in the data collection confirmed their interest and availability. The data recorded are an integral part of nursing care and the study was conducted to respect the patients' anonymity.
Results
Of the 89-member centres of the GITMO national transplant group, 19 (21%) centres participated in the study. From 1 September 2002 to 28 February 2006, the data from 1847 patients were collected. A total of six patients were excluded owing to missing data.
Demographic data
The patients' characteristics are summarised in Table 1 . The patients were sub-divided into three age-stratification groups:
paediatric patients 0-18 yrs (within paediatric HSCT units), n ¼ 262 (14.2%), adult patients 19-59 yrs, n ¼ 1231 (66.9%) elderly patients 60-74 yrs, n ¼ 348 (18.9%).
Pre-HSCT oral assessment
The oral cavity was evaluated before HSCT in all patients. 47% of the 1841 patients underwent dental X-ray to identify any underlying dental condition, which might have been a potential source of infection. A total of 580 patients were referred to a dentist and 237 (13%) received dental treatment. A total of 146 patients (8%) received tartar removal only.
Development of mucositis
Various grades of OM were developed in 1315 patients (71.4%) (see Table 2 ). Of the 262 patients aged 0-18 yrs, 142 (54.2%) developed mild or moderate OM (Grade 1 and 2 according to the WHO scale), whereas 67 of 262 patients (25.6%) developed severe OM (Grades 3 and 4).
With regards to adult patients, the occurrence of severe mucositis (Grades 3 and 4 according to the WHO scale) was identified in 300 patients (24.4%), whereas in the elderly patient group, severe mucositis was seen in 32 patients (9.2%).
These results are presented in Table 3 with a subdivision according to the age and type of transplant. The percentage of patients who underwent autologous HSCT who did not develop OM varies according to the three age groups in this study. Only 14.4% (14 patients) in the youngest group did not develop OM, whereas in the adult and elderly groups the percentage rose to 31.5% (244 patients) and 39.7% (120 patients), respectively.
In allogenic HSCT, the percentages followed a similar trend with 15.4% (23 children), 16.5% (72 adults) and 32.6% (14 elderly patients).
As far as mild to moderate OM (Grades 1 and 2 on the WHO scale) and severe OM (Grades 3 and 4 on the WHO scale) are concerned, the percentages differ according to the age group with a higher incidence in the paediatric in both patients who undergo autologous HSCT and those who undergo allogenic HSCT. The only similar data arise in paediatric and elderly patients who undergo allogenic HSCT and are affected by mild to moderate OM.
The incidence and severity of OM, depends more on the type of transplant than on age, in which the different conditioning regimens before transplant, may be more or less toxic to the oral mucosa. Autologous haematopoietic stem cells used for reconstitution of the BM (intended moreover as a 'tandem transplant' methodology, or rather sequentially, requiring repeated infusions at pre-determined intervals, preceded by chemotherapy) were used in 1174 patients (63.7%). Allogeneic HSCT from a family or unrelated donor or umbilical cord blood were performed in 628 patients (34.1%), whereas haploidentical SCT was performed in 39 patients (2.1%).
In adult patients undergoing allogeneic HSCT, the percentage of severe OM was 39.7% (173 patients) compared with 16.4% of severe mucositis arising in adult patients undergoing autologous HSCT (127 patients). The w 2 -test showed a statistically significant difference (Po0.001), with an overall rate of 2.88 (adult patients undergoing allogeneic HSCT have a 2.88 times higher risk of developing a severe-grade mucositis compared with those undergoing autologous HSCT).
Engraftment of transplanted stem cells was, in a large majority of cases, at 10-20 days after transplant (65%), with an average of 13.4 days ( ± 4.8).
The duration of OM mild/moderate (Grades 1 and 2 according to the WHO scale) is reported in Figure 1 , whereas the duration of severe mucositis (Grades 3 and 4 according to the WHO scale) is reported in Figure 2 .
Discussion
In this research, 1315 patients (71.4%) developed OM of various grades, which is lower than the frequency reported to date. 1, 4 Regarding the severity of mucositis in the various age groups, in the paediatric group 20.2% did not develop mucositis, whereas in the two other sub-groups the absence of OM was 27.3 and 39.3% respectively. This confirms the claims of Sonis, where a higher baseline proliferation fraction of cells (typical in paediatric and young patients) creates a three-fold higher risk of developing OM. 6 Severe mucositis (Grade 3 or 4) was observed more in paediatric and in adult patient groups (WHO Grade 3: 16.8 and 14.8%, respectively, Grade 4: 8.8 and 9.6%, respectively), whereas in the elderly population the severity of mucositis was much lower (6.0 and 3.2%, respectively). This difference probably relates to less aggressive treatments, which are also in relation to age.
The w 2 -test between paediatric and adult patient groups with respect to the development of severe mucositis compared with mild/moderate mucositis did not show a statistically significant difference (P ¼ 0.6862), whereas a statistically significant difference was seen between paediatric and elderly patient groups (Po0.0001).
The analysis regarding incidence and severity of OM in the three age groups and according to the type of transplant (autologous or allogeneic) have given results that initially seem contradictory.
In the paediatric patients undergoing autologous or autologous 'tandem' HSCT, severe OM was shown in 26 cases (26.8% of 97 transplants), whereas 41 paediatric patients developed severe mucositis after allogeneic HSCT (27.6% of 149 transplants). The w 2 -test undertaken with this data did not show a statistically significant difference (P ¼ 0.8540). These data confirm those in the literature. Pre-HSCT conditioning regimes that used high-dose chemotherapy in association with TBI, used in patients undergoing allogeneic HSCT, combined with MTX post HSCT (commonly used as a prophylaxis for GvHD) induce OM. [1] [2] [3] 15, 16 The difference observed in the paediatric patient group is probably related to the fact that patients are affected by central nervous system tumours (which represents the second most common tumour in infancy after acute lymphoblastic leukaemia) and who are undergoing autologous HSCT. They developed severe OM, probably due to heavy pre-treatment before the transplant procedure. 17 Moreover, some chemotherapy used in these patients have synergic properties (for example, etoposide and thiotepa) and, when used in combination, are responsible for increasing the onset of mucositis. 18 Also regarding the development of severe mucositis, in the paediatric and adult groups, the difference was not statistically significant (P ¼ 0.0870).
Comparing paediatric and adult groups, undergoing conditioning regimens with chemotherapy and TBI, a statistically significant difference was seen in the incidence of severe mucositis: the w 2 -test showed a result of Po0.0051, confirming previously reported findings regarding the stomato-toxicity of TBI. 1, 15, 16 The duration of mucositis is influenced by the phase of marrow aplasia following HSCT and the resolution of mucositis generally coincides, with marrow reconstitution following stem cell re-infusion. 19 
Conclusion
This research, the collaboration of nurses within 19 GITMO national group member centres, was aimed at describing the incidence, severity and duration of OM in patients undergoing HSCT, as well as setting up an exchange and data collection network regarding nursing care issues in the various centres. The study confirmed that currently present in the literature, also if the percentage of elderly patients developing mucositis was lower (60.6% compared with 75-99%). [1] [2] [3] [4] As there are a large number of patients observed, it might be useful to conduct a multivariate analysis, which could bring further value to the precious work undertaken by the nurses. Further areas for research could also include the revision of nurses education for patients in how to care for the oral cavity and how to prevent post HSCT infections.
The use of such a database could also help in the development of evidence-based practise with more detailed observations and data collection providing information on correlations between nursing care interventions and outcomes.
The experience of a multicentre database, other than providing a global view of the incidence and severity of OM in patients undergoing HSCT, has allowed many of the participating centres to adopt routine evaluation and assessment of the oral cavity as part of nursing care.
